C-proSP-B: A Possible Biomarker for Pulmonary Diseases?

Area of Science:

• Pulmonary Medicine
• Biomarker Discovery
• Respiratory Diseases

Background:

• Surfactant proteins A and D (SP-A, SP-D) in serum indicate alveolar epithelial barrier injury and serve as pulmonary disease biomarkers.
• Data on surfactant protein B (SP-B) as a biomarker are limited.

Purpose of the Study:

• To evaluate the potential of immature SP-B pre-proteins as a biomarker for pulmonary diseases.
• To assess if C-terminal pro-SP-B (C-proSP-B) can serve as a diagnostic marker.

Main Methods:

• Measured C-proSP-B levels in serum from 283 patients with various chronic lung diseases using an electrochemiluminescence immunoassay.
• Correlated C-proSP-B levels with lung function and clinical parameters.

Main Results:

• The highest C-proSP-B levels were observed in patients with idiopathic pulmonary fibrosis (IPF).
• Multivariate analysis demonstrated that C-proSP-B levels could differentiate IPF patients from those with other pulmonary conditions (p < 0.0001).
• No significant correlation was found between C-proSP-B levels and lung function, smoking history, or disease extent.

Conclusions:

• Immature SP-B pre-proteins, specifically C-proSP-B, may function as biomarkers for pulmonary diseases involving alveolar or interstitial damage, such as interstitial lung diseases (ILDs) and especially IPF.
• Further research is needed to clarify the role of SP-B pre-proteins in the long-term monitoring of these conditions.